| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA644: Entrectinib for treating NTRK fusion-positive solid tumours |
|
Medicine details |
|
| Medicine name | entrectinib (Rozlytrek®) |
| Formulation | 100 mg and 200 mg capsule |
| Reference number | 3021 |
| Indication | As monotherapy for the treatment of adults and paediatric patients 12 years of age and older, with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory treatment options |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 30/06/2020 |
| NICE guidance | TA644: Entrectinib for treating NTRK fusion-positive solid tumours |
| Commercial arrangement | PAS + CAA |